Clinical Trial Detail

NCT ID NCT01450696
Title HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Capecitabine + Cisplatin + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST